Postmenopausal Vaginal Atrophy Drugs Market Report Provides Point To Point Information of the Market Capacity, Production, Market Share, Revenue and Growth Rate

Menopausal atrophy (menopausal atrophy (PVA)) is the reduction of estrogen production after menopause, which is also called vaginal atrophy. Less estrogen leads to thinning of vaginal tissue, drying and reduction of elasticity. Various factors that lead to a decrease in estrogen levels include postmenopausal, surgical menopause, pelvic radiation therapy and chemotherapy during breastfeeding. Symptoms of vaginal atrophy include redness, burning, itching, dyspareunia, and irritation. PVA diagnosis includes pelvic examination, vaginal smear test, vaginal activity test, blood test, urinalysis.

A gradual shift from non-estrogen therapy to systemic estrogen therapy, such as benign healthcare reforms, high unmet medical demand across emerging economies, vaginal gels and patches, leads the market. In addition, higher prevalence of menopausal atrophy accelerates market growth. However, the risks associated with low diagnostic rates and existing treatment options limit the market. The emergence of new safety-enhanced drugs is expected to meet unmet needs and provide profitable market growth opportunities.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-toc-and-sample/4378?utm_source=sy

The key players operating in the global PVA market include
• Actavis plc
• Bionovo Inc.
• Endoceutics Inc.
• Novo Nordisk A/S
• Pfizer Inc.
• Teva Pharmaceuticals Ltd.
• Therapeutics MD Inc.
• Shionogi & Company Limited
• Allergan plc
• Shionogi & Co. Ltd.

The report segments the global PVA market based on therapy type and drug forms. Based on therapy type, the market is categorized into estrogen-based drugs (Premarin, Vagifem, Estrace, Estring and Femring) and non-estrogen-based drugs (BZA/CE, Osphena, and Vaginorm). Based on drug forms, the market is categorized as vaginal gels, creams, tablets, rings, and patches. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Make an Enquiry before Buy @ https://www.alliedmarketresearch.com/purchase-enquiry/4378?utm_source=sy

Key Benefits
• The study provides an in-depth analysis of the global PVA market and the current trends and future estimations to elucidate the imminent investment pockets.
• The report presents quantitative analysis of the market from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
• Extensive analysis of the market based on product assists to understand the trends in the industry.
• Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the industry.

Access Full Summery @ https://www.alliedmarketresearch.com/postmenopausal-vaginal-atrophy-drugs-market?utm_source=sy

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Contact:

David Correa

5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States

Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975

help@alliedmarketresearch.com

This release was published on openPR.